![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 25, 22115-22118, June 21, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Department of Biochemistry, Dartmouth Medical School,
Hanover, New Hampshire 03755 and the § Harvard
Microchemistry and Proteomics Analysis Facility, Department of
Molecular and Cellular Biology, Harvard University,
Cambridge, Massachusetts 02138
Received for publication, April 1, 2002, and in revised form, April 25, 2002
This study describes a method for the
identification of the substrates of specific serine kinases. An
antibody specific for the phosphomotif generated by the kinase is used
to isolate phosphorylated substrates by immunoprecipitation, and the
isolated proteins are identified by tandem mass spectrometry of
peptides. This method was applied to the identification of substrates
for the protein kinase Akt, which specifically
phosphorylates the RXRXXS/T motif. 3T3-L1 adipocytes were treated with insulin to activate Akt, and the
putative Akt substrate proteins were isolated by immunoprecipitation with an antibody against the phospho form of this motif. This led to
the identification of a novel 160-kDa substrate for Akt. The 160-kDa
substrate for Akt, which was designated AS160, has a Rab GAP domain.
Recombinant AS160 was shown to be a substrate for Akt, and two sites of
phosphorylation, both in RXRXXS/T motifs, were
identified by mass spectrometry and mutation. Insulin treatment of
adipocytes caused AS160 to redistribute from the low density microsomes
to the cytosol.
Protein phosphorylation is a key cellular regulatory mechanism.
The human genome contains ~1000 kinases. A major issue is to identify
the protein substrates for each kinase. A number of different
approaches have been developed (reviewed in Ref. 1). These include:
in vitro phosphorylation of cell homogenates with recombinant kinases, screening of expression libraries with recombinant kinases, searching for kinase interacting proteins by the yeast two-hybrid screen, and the generation of mutated kinases that can
function only with an ATP derivative. Each of these methods has its
advantages and limitations, and additional methods are needed.
Each serine kinase typically phosphorylates Ser/Thr within a particular
motif, and for many kinases the motif has been defined through
identification of the sites of phosphorylation on substrate proteins
and on peptide libraries (2). Phosphospecific antibodies against the
phosphorylated form of these motifs are available or can be generated.
Thus, immunoprecipitation with these antibodies, when combined with
tandem mass spectrometry of tryptic peptides, offers an approach for
the isolation and identification of substrates for specific serine
kinases. In the past this approach has been used for the identification
of substrates for tyrosine kinases through the use of antibodies
against phosphotyrosine, but to our knowledge it has not previously
been used with serine kinases.
In the present study, we applied this method to find substrates for the
protein kinase Akt (also known as protein kinase B), which specifically
phosphorylates Ser or Thr in the motif RXRXXS/T (3). We have employed 3T3-L1 adipocytes, a cell type in which Akt is
rapidly activated by insulin treatment (4). This method has led to the
isolation of a novel target for Akt that contains a Rab
GAP1 domain and two PTB domains.
Antibodies--
A key reagent for this study is the antibody for
the Akt phosphomotif RXRXXpS/T, where
X is any amino acid. This antibody, which is referred as the
PAS antibody (phospho Akt
substrate), was purchased from Cell Signaling Technology,
Beverly, MA (catalog number 9611). It is an affinity-purified rabbit
antibody that has been shown to react specifically with the Akt
phosphomotif in 12 known Akt substrates (literature from Cell Signaling
Technology). The method used to generate the antibody is not described,
but presumably an antiserum with this specificity could be generated by
immunization with a mixture of phosphopeptides in which all amino acids
except Cys were put into the X positions, and the antibody
could be affinity-purified on the immobilized mixture of
phosphopeptides. An affinity-purified antibody against the carboxyl
terminal 12 amino acids of mouse AS160 (PTNDKAKAGNKP) was generated as
described in Ref. 5. Antibody against the FLAG tag (catalog number
F-3165) was purchased from Sigma.
Plasmids--
The cDNA encoding AS160 (6) in pBluescript SK
vector was kindly provided by the Kazusa DNA Research Institute. It was
amplified by PCR with a 5' primer containing a NotI site and
a 3' primer with a BamHI site and then spliced into the
p3XFLAG-CMV-10 vector (Sigma). This yielded AS160 with a triple FLAG
tag at the amino terminus. Mutants of AS160 in the p3XFLAG-CMV-10
vector were generated by PCR using the QuikChange XL site-directed
mutagenesis kit from Stratagene, and the mutations were verified by DNA sequencing.
Cell Culture--
3T3-L1 adipocytes were carried as fibroblasts
and differentiated as described (7). Cells were placed in serum-free
Dulbecco's modified Eagle's medium for 2 h before use and
were then treated with 160 nM insulin for 10 min, unless
stated otherwise. COS7L cells, purchased from Invitrogen, were
transfected with 10 µg of plasmid DNA/10-cm plate with the
LipofectAMINE 2000 reagent (Invitrogen) according to the
manufacturer's instructions.
Immunoprecipitation and Immunoblotting--
For isolation of the
proteins with the PAS antibody, 10-cm plates of adipocytes were each
treated with insulin or not, washed with phosphate-buffered saline, and
solubilized in 0.6 ml of 4% SDS, 10 mM dithiothreitol, 300 mM NaCl, 100 mM Hepes, pH 7.5, with protease
inhibitors (10 µM concentration each of pepstatin, leupeptin, and EP475) at 100 °C for 5 min. The SDS lysate was treated with 25 mM N-ethylmaleimide to cap the
thiol groups and diluted with 5 ml of 1.7% thesit, 150 mM
NaCl, 50 mM Hepes, pH 7.5. The mixture was centrifuged at
20,000 rpm for 30 min, and the infranatant was passed through a
0.45-micron filter to remove residual triglyceride droplets. PAS
antibody (7 µg per plate) was added, and after 2 h the
immunoprecipitate was collected on protein A-Sepharose (10 µl per
plate) for 2 h. The beads were washed four times with 0.5%
thesit, 150 mM NaCl, 50 mM Hepes, pH 7.5, and
the immunoprecipitates were solubilized in SDS sample buffer at
100 °C for 5 min.
For immunoblotting proteins were separated by SDS-PAGE and then
transferred to electrophoretically to Immobilon-P (Millipore). The
membranes were blocked with 10 mg/ml bovine serum albumin, 0.3% Tween
20, 150 mM NaCl, 20 mM Tris-Cl, pH 7.5, treated
with primary antibody in the same solution, washed, treated with
horseradish peroxidase-conjugated secondary antibody, and developed
with the chemiluminescence reagent Supersignal (Pierce).
Tandem Mass Spectrometry--
Proteins were separated by
SDS-PAGE, and the gel was stained with the colloidal Coomassie Blue
reagent (Invitrogen). Proteins of interest were digested in gel with
trypsin. The tryptic peptides were sequenced by microcapillary liquid
chromatography MS/MS on an ion trap mass spectrometer
(ThermoFinnigan LCDQ DECA XP), as described (8). To detect a
specific site of phosphorylation, a targeted ion MS/MS experiment was
conducted for each putative phosphopeptide. In these experiments the
predicted precursor mass-to-charge ratio of the phosphopeptide was
subjected to MS/MS for the entire chromatographic run. This procedure
significantly increases detection sensitivity by capturing only the
peptide of interest at the moment of its chromatographic elution while
excluding peptidic background.
Isolation of Insulin-elicited Phosphoproteins with the PAS
Antibody--
3T3-L1 adipocytes were untreated or treated with
rapamcyin, wortmannin, or LY294002 and then subsequently exposed to
insulin or not. Rapamycin inhibits insulin activation of the 70-kDa S6 kinase but not of Akt, whereas wortmannin and LY294002 inhibit activation of PI 3-kinase and thereby of Akt (9, 10). SDS samples of
the cells were blotted with the PAS antibody (Fig. 1A). Seven insulin-elicited
phosphoproteins (pp250, pp160, pp105, pp75, pp47, pp43, and pp32) were
detected. Wortmannin and LY294004 blocked the phosphorylation of all of
these except possibly pp75, but rapamycin blocked only the
phosphorylation of pp32. These results thus suggested that pp250,
pp160, pp105, pp47, and pp43 are Akt substrates, whereas pp32 may be an
S6 kinase substrate. Insulin also caused a decrease in the
phosphorylation of a 60-kDa protein, which was blocked by wortmannin
and LY294004, but not by rapamycin. In Fig. 1A insulin
treatment was for 10 min. Examination of the time course for changes in
phosphorylation detected with the PAS antibody showed that for each
phosphoprotein the change was approximately maximal after 10 min of
insulin treatment (data not shown).
To isolate the proteins that underwent changes in phosphorylation, we
carried out immunoprecipitation with the PAS antibody. Cells were first
lysed in SDS to denature the proteins and thereby expose the
phosphopeptide motifs, and then an excess of nonionic detergent was
added and the immunoprecipitation performed. By this approach it was
possible to isolate pp250, pp160, pp105, pp75, and pp60 (Fig.
1B). No pp32 was detected in the immunoprecipitate, and the
strong signal from the antibody heavy chain precluded determining
whether pp47 and pp43 were present. The immunoprecipitate derived from
insulin-treated cells showed slightly more of the pp250, pp160, pp105,
and pp75 than did that derived from untreated cells. However, the
difference was not as large as was observed with blotting of the cell
lysates (Fig. 1A). A possible explanation is that the PAS
antibody, which is a mixture, contains only a limited amount of
antibody against any specific RXRXXS/T sequence, and thus the percent yield upon immunoprecipitation was
antibody-limited and so less for the insulin sample. Considerably more
pp60 was present in the immunoprecipitate derived from untreated
adipocytes. Subsequently we found that pp32 could be isolated by
immunoprecipitation from a nonionic detergent lysate of adipocytes (see
Fig. 3A).
Identification of the Insulin-elicited
Phosphoproteins--
Immunoprecipitations of the phosphoproteins from
SDS/nonionic detergent lysates of untreated and insulin-adipocytes were
performed on a large scale (six 10-cm plates). The pp250, pp160, pp105, pp75, and pp60 bands were separated by SDS-PAGE, subjected to tryptic
digestion, and the peptides sequenced by MS/MS. In a separate isolation
pp32 was identified in this way after isolation from a nonionic
detergent lysate of the LDM fraction of adipocytes, where it was most
abundant (data not shown).
Initially we have focused on pp160. MS/MS sequence analysis of the
sample from insulin-treated cells yielded 15 peptides identical to
those in the human protein gi7662198 and thus indicated that pp160 is
the mouse version of this protein. gi7662198 is a protein of 1299 amino
acids whose function is unknown. Its cDNA was previously cloned as
part of a large scale cDNA cloning project (6). The protein is
predicted to contain two PTB domains and a Rab GAP domain (Fig.
2). It has two sites, Ser-588 and
Thr-642, that are predicted to lie in excellent motifs for Akt
phosphorylation (2).
To establish the identity of pp160 definitively, we raised an antibody
against the carboxyl terminal sequence of the mouse protein and used
it, together with the PAS antibody, in reciprocal immunoprecipitations
and immunoblottings with nonionic detergent lysates of basal and
insulin-treated adipocytes. The results exhibited the pattern expected
(Fig. 3). Immunoprecipitation from the
insulin lysate with the antibody against pp160 (hereafter referred to as AS160 for Akt substrate of 160
kDa) yielded a 160-kDa protein detected by the PAS antibody (lane
4), and immunoprecipitation from the insulin lysate with the PAS
antibody yielded a 160-kDa protein detected by the AS160 antibody
(lane 6). Phosphorylation of AS160 was accompanied by a
slight decrease in electrophoretic mobility (compare lanes 7 and 8).
MS/MS sequencing of the pp32 band from insulin-treated adipocytes
identified 14 peptides from the 29-kDa ribosomal protein S6 together
with smaller numbers of peptides from the similarly sized ribosomal S2,
S3, and S3A proteins. Possibly these immunoprecipitated as a complex.
It is likely that the PAS antibody reacted with the S6 protein in this
mixture. The S6 protein is known to be phosphorylated by the 70-kDa S6
kinase on the Ser-236, which is in an RXRXXS
sequence (RRRLSS236L) (11).
The pp60 band, obtained from the lysate, of untreated cells contained
the mouse version of the well characterized rat adipocyte protein
perilipin. Perilipin is a 56-kDa protein that is associated with the
lipid droplets; it is constitutively phosphorylated, is heavily
phosphorylated in response to agents that activate cAMP-dependent protein kinase, and undergoes
dephosphorylation in response to insulin (12). The sites of perilipin
phosphorylation have not been identified, but presumably the PAS
antibody reacts with one of these. Perilipin contains only one Ser/Thr
that is in a motif likely to react with this antibody, Ser-385
(KGRAMS385L).
The pp 250-, 105-, and 75-kDa bands each contained peptides from
several proteins. We are currently generating antibodies against the
candidate in each band most likely to be the one reacting with the PAS
antibody, to identify it. None of the proteins present in these bands
are on the list of known Akt substrates (3).
Sites of Phosphorylation in AS160 and Phosphorylation by
Akt--
To determine whether AS160 was phosphorylated on one or both
of the predicted Akt sites (Fig. 2), the two predicted tryptic phosphopeptides were targeted for MS/MS in the tryptic digest of mouse
AS160 isolated from insulin-treated adipocytes. The expressed sequence
tag data base contains portions of the sequence of mouse AS160,
and from these the sequences of the two mouse tryptic peptides corresponding to human tryptic peptides with Ser-588 and Thr-642 were
obtained. The mouse and human sequences are:
LGS588M(T)DSFER and AHT642FSHPPSSS(T)R(K),
where each amino acid in parentheses is for the human sequence. The two
tryptic phosphopeptides were detected by targeted MS/MS, and the
resulting fragmentation spectra established that the sites of
phosphorylation were Ser-588 and Thr-642.
To determine directly whether AS160 was a substrate for Akt, we
examined the phosphorylation of recombinant AS160, as well as mutant
forms with Ser-588, Thr-642, or both converted to Ala, by recombinant
Akt 1. Phosphorylation was detected by immunoblotting with the PAS
antibody. The data in Fig. 4 shows that
Akt phosphorylation of AS160 and its S588A mutant yielded AS160 that
was detected well by the PAS antibody. In contrast, Akt phosphorylation
of the T642A mutant yielded an AS160 that reacted very weakly with the
PAS antibody (see the legend to Fig. 4), and phosphorylation of the
double mutant resulted in an AS160 that showed no detectable reaction
with the PAS antibody. Thus, Akt phosphorylated AS160 on Thr-642 and
probably on Ser-588. The PAS antibody probably binds more strongly to
the phosphopeptide sequence containing Thr-642 than to that containing
Ser-588.
We have also examined the phosphorylation of AS160 and the
T642A/S588A mutant after isolation by immunoprecipitation with anti-FLAG from SDS/thesit lysates of basal and insulin-treated transfected COS7 cells. In this in vivo system insulin
stimulated phosphorylation of AS160 3-fold, and the T642A/S588A
mutant showed almost no phosphorylation, as assessed by blotting with
the PAS antibody (data not shown).
Subcellular Distribution of AS160--
In untreated adipocytes
AS160 was concentrated in the LDM fraction (Fig.
5A). Treatment with insulin
caused a marked redistribution of AS160 from the LDM to the cytosol. As
is the case for AS160 phosphorylation, treatment with wortmannin or
LY294002 inhibited the insulin-elicited redistribution (Fig.
5B). One of the components of the LDM is vesicles containing
the glucose transporter GLUT4 (13). In response to insulin these move
to and fuse with the plasma membrane (reviewed in Ref. 14). We isolated
GLUT4 vesicles from the LDM by immunoadsorption (13) and found by
immunoblotting that AS160 was not located in these vesicles (data not
shown).
Tissue Distribution of AS160--
SDS lysates of mouse tissues
were immunoblotted for AS160 with the AS160 antibody. All the tissues
examined (brain, testes, spleen, kidney, pancreas, lung, thymus, liver,
heart, quadriceps, and brown and white fat) showed a band at ~160
kDa, with the strongest signals in the brain and pancreas (data not
shown). Thus, these results indicate that AS160 has a widespread tissue
distribution. Previously the mRNA for AS160 was shown to be widely
expressed in human tissues (6).
This study illustrates a method for the isolation of substrates
for serine kinases by means of phosphomotif-specific antibodies, which
are now becoming commercially available. Application of the method
requires that the serine kinase have a specificity for Ser/Thr within a
fairly well defined motif and that the antibody against the
phosphomotif functions in immunoprecipitation. The method is best
applied in cell types where the kinase can be activated by some agent
so that the phosphoproteins reacting with the phosphomotif-specific antibody after activation can be compared with those seen before activation. Using this approach, we have identified one novel substrate
for Akt, AS160, and expect to identify at least two more, pp250 and pp105.
One complication of the method is that in a number of instances several
kinases have very similar specificity with respect to the motif in
which the Ser/Thr lies, and consequently the definitive identification
of the activated kinase responsible for phosphorylation requires
information from other types of experiments. Our results illustrate
this situation. The insulin-elicited pp32 proved to be ribosomal S6
protein that was phosphorylated by S6 kinase rather than Akt. In
addition, the serum- and glucocorticoid-induced protein kinase has a
specificity that is very similar to that of Akt and is activated by
insulin (15). Consequently, it is possible that some of the substrates
detected with the PAS antibody are targets of this kinase, rather than
or in addition to Akt.
The AS160 protein is a previously undescribed Akt substrate. Our
results show that insulin treatment of adipocytes causes its
subcellular redistribution and are consistent with the proposal that
this effect is due to its phosphorylation. In its overall structure
AS160 partially resembles a recently characterized GAP for Rab6, which
has a single PTB domain in its NH2 terminus and a Rab GAP
domain 34% identical to the one in AS160 (16). Since the Rabs are key
proteins in membrane trafficking (17), phosphorylation of AS160 by Akt
may function to connect insulin signaling to membrane trafficking
through an effect on its GAP activity toward a particular Rab.
Insulin-stimulated trafficking of GLUT4 to the plasma membrane requires
activation of PI 3-kinase, and there is evidence that Akt is a
downstream kinase required for this process (14, 18). Thus, despite the
fact that AS160 is not located in GLUT4 vesicles, it remains a
candidate to be a component of the signaling pathway from the insulin
receptor to GLUT4 trafficking. Efforts are under way to test this
possibility and to identify the Rab for which AS160 is a GAP.
*
This work was supported by National Institutes of Health
Grants DK25336 and DK42816 (to G. E. L.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
Permanent address: Dept. of Chemistry, Abilene Christian
University, Abilene, TX 79699.
Published, JBC Papers in Press, May 6, 2002, DOI 10.1074/jbc.C200198200
The abbreviations used are:
GAP, GTPase-activating protein;
LDM, low density microsomes;
MS/MS, tandem
mass spectrometry;
pp, phosphoprotein;
PTB, phosphotyrosine binding;
thesit, octaethyleneglycol dodecyl ether;
PI, phosphatidylinositol;
MOPS, 4-morpholinepropanesulfonic acid.
ACCELERATED PUBLICATION
A Method to Identify Serine Kinase Substrates
Akt PHOSPHORYLATES A NOVEL ADIPOCYTE PROTEIN WITH A Rab
GTPASE-ACTIVATING PROTEIN (GAP) DOMAIN*
,
,
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (83K):
[in a new window]
Fig. 1.
Proteins reacting with the PAS antibody.
A, adipocytes were treated with no addition (No
add), 20 nM rapamycin (RAP), 200 nM wortmannin (WOR), or 75 µM
LY294002 (LY2) for 45 min, and then insulin was added for 10 min. SDS lysates were prepared and blotted with the PAS antibody. The
1× load is 3% of a 10-cm plate. B, SDS/thesit lysates of
untreated and insulin-treated adipocytes were immunoprecipitated
(IP) with the PAS antibody, and the immunoprecipitates were
immunoblotted with this antibody. The 1× load is derived from 15% of
a 10-cm plate. Repetitions of both experiments gave similar
results.
![]()
View larger version (5K):
[in a new window]
Fig. 2.
Schematic diagram of human AS160. The
domains predicted by the Pfam program (pfam.wustl.edu) and the two
sites of phosphorylation are shown.

View larger version (36K):
[in a new window]
Fig. 3.
Identification of pp160 as AS160. Basal
and insulin-treated 10-cm plates of adipocytes were lysed in 1 ml of
3% thesit, 150 mM NaCl, 40 mM Hepes, pH 7.5, with phosphatase inhibitors (10 mM sodium pyrophosphate, 10 mM NaF, 2 mM EDTA, 10 mM sodium
vanadate) and protease inhibitors. The lysates were cleared by
centrifugation, the supernatants were immunoprecipitated with the PAS
antibody or the antibody against AS160, and the immunoprecipitates were
immunoblotted with both antibodies. The load on each lane was derived
from 20% of a 10-cm plate. A repetition of this experiment gave
similar results.

View larger version (29K):
[in a new window]
Fig. 4.
Phosphorylation of wild-type and mutant AS160
in vitro. COS7L cells were transfected with plasmids
encoding the wild-type (WT), T642A (T/A), S588A
(S/A), or double mutant T642A/S588A
(TS/AA) of AS160. The cells were lysed in 2 ml/10-cm plate
of 1.7% thesit, 150 mM NaCl, 50 mM Hepes, pH
7.5, with protease inhibitors, and AS160 was immunoprecipitated with
anti-FLAG (5 µg) and protein G-Sepharose (40 µl). Aliquots of the
immunoprecipitates (12 µl) were treated with no, 0.1, or 0.5 µg of
recombinant active Akt1 (Upstate Biotechnology, catalog number 14-276)
in 100 µM ATP, 75 mM MgCl2, 25 mM
-glycerophosphate, 5 mM EGTA, 1 mM dithiothreitol, 1 mM sodium vanadate, 20 mM MOPS, pH 6.8 (40 µl), for 30 min at 30 °C. Portions
of the samples containing equal amounts of the recombinant AS160, as
assessed by blotting for the FLAG epitope, were blotted with the PAS
antibody. Upon prolonged exposure Akt-treated T642A samples showed a
weak signal, whereas Akt-treated T642A/S588A samples showed no
signal. A repetition of this experiment with the wild-type and T642A
AS160 gave similar results.

View larger version (34K):
[in a new window]
Fig. 5.
Insulin-stimulated redistribution of
AS160. A, untreated and insulin-treated adipocytes were
fractionated into LDM, plasma membrane (PM), high density
microsomes (HDM), mitochondria and nuclei (M/N),
and cytosol (CYT), as described in Ref. 13, with the
modification that the buffer included phosphatase inhibitors (1 mM sodium vandate, 50 mM NaF, 5 mM
sodium pyrophosphate, 5 mM
-glycerophosphate) and
protease inhibitors. Samples were immunoblotted for AS160 and with the
PAS antibody. The 1× load was 25 µg. B, same as in
A, except that cells were treated with no addition, 200 nM wortmannin, or 75 µM LY294002, as in Fig.
1. Repetitions of these experiments gave similar results.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
FOOTNOTES
These authors contributed equally to this study.
To whom correspondence should be addressed: Dept. of
Biochemistry, Vail Bldg., Dartmouth Medical School, Hanover, NH 03755. Tel.: 603-650-1627; Fax: 603-650-1128; E-mail:
gustav.e.lienhard@dartmouth.edu.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Knebel, A.,
Morrice, N.,
and Cohen, P.
(2001)
EMBO J.
20,
4360-4369[CrossRef][Medline]
[Order article via Infotrieve]
2.
Yaffe, M. B.,
Leparc, G. G.,
Lai, J.,
Obata, T.,
Volinia, S.,
and Cantley, L. C.
(2001)
Nat. Biotechnol.
19,
348-353[CrossRef][Medline]
[Order article via Infotrieve]
3.
Lawlor, M. A.,
and Alessi, D. R.
(2001)
J. Cell Sci.
114,
2903-2910[Medline]
[Order article via Infotrieve]
4.
Hill, M. M.,
Clark, S. F.,
Tucker, D. F.,
Birnbaum, M. J.,
James, D. E.,
and Macaulay, S. L.
(1999)
Mol. Cell. Biol.
19,
7771-7781 5.
Lampere, L.,
and Lienhard, G. E.
(1992)
Endocrinology
131,
2196-2202[Abstract]
6.
Nagase, T.,
Ishikawa, K.,
Miyajima, N.,
Tanaka, A.,
Kotani, H.,
Nomura, N.,
and Ohara, O.
(1998)
DNA Res.
5,
31-39[Abstract]
7.
Frost, S. C.,
and Lane, M. D.
(1985)
J. Biol. Chem.
260,
2646-2652 8.
Wu, X.,
Ranganathan, V.,
Weisman, D. S.,
Heine, W. F.,
Ciccone, D. N.,
O'Neill, T. B.,
Crick, K. E.,
Pierce, K. A.,
Lane, W. S.,
Rathbun, G.,
Livingston, D. M.,
and Weaver, D. T.
(2000)
Nature
405,
477-482[CrossRef][Medline]
[Order article via Infotrieve]
9.
Fingar, D. C.,
Hausdorff, S. F.,
Blenis, J.,
and Birnbaum, M. J.
(1993)
J. Biol. Chem.
268,
3005-3008 10.
Somwar, R.,
Niu, W.,
Kim, D. Y.,
Sweeney, G.,
Randhawa, V. K.,
Huang, C.,
Ramlal, T.,
and Klip, A.
(2001)
J. Biol. Chem.
276,
46079-46087 11.
Volarevic, S.,
and Thomas, G.
(2001)
Prog. Nucleic Acid Res. Mol. Biol.
65,
101-127[Medline]
[Order article via Infotrieve]
12.
Clifford, G. M.,
McCormick, D. K. T.,
Londos, C.,
Vernon, R. G.,
and Yeaman, S. J.
(1998)
FEBS Lett.
435,
125-129[CrossRef][Medline]
[Order article via Infotrieve]
13.
Morris, N. J.,
Ross, S. A.,
Lane, W. S.,
Moestrup, S. K.,
Petersen, C. M.,
Keller, S. R.,
and Lienhard, G. E.
(1998)
J. Biol. Chem.
273,
3582-3587 14.
Simpson, F.,
Whitehead, J. P.,
and James, D. E.
(2001)
Traffic
2,
2-11[CrossRef][Medline]
[Order article via Infotrieve]
15.
Kobayashi, T.,
and Cohen, P.
(1999)
Biochem. J.
339,
319-328[CrossRef][Medline]
[Order article via Infotrieve]
16.
Cuif, M.,
Possmayer, F.,
Zander, H.,
Bordes, N.,
Jollivet, F.,
Couedel-Courteille, A.,
Janoueix-Lerosey, I.,
Langsley, G.,
Bornens, M.,
and Goud, B.
(1999)
EMBO J.
18,
1772-1782[CrossRef][Medline]
[Order article via Infotrieve]
17.
Zerial, M.,
and McBride, H.
(2001)
Nat. Rev. Mol. Cell. Biol.
2,
107-119[CrossRef][Medline]
[Order article via Infotrieve]
18.
Cho, H., Mu, J.,
Kim, J. K.,
Thorvaldsen, J. L.,
Chu, Q.,
Chrenshaw, E. B., III,
Kaestner, K. H.,
Bartolomei, M. S.,
Shulman, G. I.,
and Birnbaum, M. J.
(2001)
Science
292,
1728-1731
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
H. C. Dreyer, M. J. Drummond, E. L. Glynn, S. Fujita, D. L. Chinkes, E. Volpi, and B. B. Rasmussen Resistance exercise increases human skeletal muscle AS160/TBC1D4 phosphorylation in association with enhanced leg glucose uptake during postexercise recovery J Appl Physiol, December 1, 2008; 105(6): 1967 - 1974. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Stockli, J. R. Davey, C. Hohnen-Behrens, A. Xu, D. E. James, and G. Ramm Regulation of Glucose Transporter 4 Translocation by the Rab Guanosine Triphosphatase-Activating Protein AS160/TBC1D4: Role of Phosphorylation and Membrane Association Mol. Endocrinol., December 1, 2008; 22(12): 2703 - 2715. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Shi, A. Burkart, S. M. Nicoloro, M. P. Czech, J. Straubhaar, and S. Corvera Paradoxical Effect of Mitochondrial Respiratory Chain Impairment on Insulin Signaling and Glucose Transport in Adipose Cells J. Biol. Chem., November 7, 2008; 283(45): 30658 - 30667. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ishikura and A. Klip Muscle cells engage Rab8A and myosin Vb in insulin-dependent GLUT4 translocation Am J Physiol Cell Physiol, October 1, 2008; 295(4): C1016 - C1025. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Sakamoto and G. D. Holman Emerging role for AS160/TBC1D4 and TBC1D1 in the regulation of GLUT4 traffic Am J Physiol Endocrinol Metab, July 1, 2008; 295(1): E29 - E37. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. C. Cha, N. R. Oak, S. Kang, T.-A. Tran, S. Kobayashi, S.-H. Chiang, D. G. Tenen, and O. A. MacDougald Phosphorylation of CCAAT/Enhancer-binding Protein {alpha} Regulates GLUT4 Expression and Glucose Transport in Adipocytes J. Biol. Chem., June 27, 2008; 283(26): 18002 - 18011. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Bouzakri, P. Ribaux, A. Tomas, G. Parnaud, K. Rickenbach, and P. A. Halban Rab GTPase-Activating Protein AS160 Is a Major Downstream Effector of Protein Kinase B/Akt Signaling in Pancreatic {beta}-Cells Diabetes, May 1, 2008; 57(5): 1195 - 1204. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. B. Taylor, D. An, H. F. Kramer, H. Yu, N. L. Fujii, K. S. C. Roeckl, N. Bowles, M. F. Hirshman, J. Xie, E. P. Feener, et al. Discovery of TBC1D1 as an Insulin-, AICAR-, and Contraction-stimulated Signaling Nexus in Mouse Skeletal Muscle J. Biol. Chem., April 11, 2008; 283(15): 9787 - 9796. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Chavez, W. G. Roach, S. R. Keller, W. S. Lane, and G. E. Lienhard Inhibition of GLUT4 Translocation by Tbc1d1, a Rab GTPase-activating Protein Abundant in Skeletal Muscle, Is Partially Relieved by AMP-activated Protein Kinase Activation J. Biol. Chem., April 4, 2008; 283(14): 9187 - 9195. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Montessuit, I. Papageorgiou, and R. Lerch Nuclear Receptor Agonists Improve Insulin Responsiveness in Cultured Cardiomyocytes through Enhanced Signaling and Preserved Cytoskeletal Architecture Endocrinology, March 1, 2008; 149(3): 1064 - 1074. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Miyamoto, N. Oshiro, K.-i. Yoshino, A. Nakashima, S. Eguchi, M. Takahashi, Y. Ono, U. Kikkawa, and K. Yonezawa AMP-activated Protein Kinase Phosphorylates Golgi-specific Brefeldin A Resistance Factor 1 at Thr1337 to Induce Disassembly of Golgi Apparatus J. Biol. Chem., February 15, 2008; 283(7): 4430 - 4438. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. F. Howlett, A. Mathews, A. Garnham, and K. Sakamoto The effect of exercise and insulin on AS160 phosphorylation and 14-3-3 binding capacity in human skeletal muscle Am J Physiol Endocrinol Metab, February 1, 2008; 294(2): E401 - E407. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kumar, T. E. Harris, S. R. Keller, K. M. Choi, M. A. Magnuson, and J. C. Lawrence Jr. Muscle-Specific Deletion of Rictor Impairs Insulin-Stimulated Glucose Transport and Enhances Basal Glycogen Synthase Activity Mol. Cell. Biol., January 1, 2008; 28(1): 61 - 70. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. I. Welsh, S. E. Leney, B. Lloyd-Lewis, M. Wherlock, A. J. Lindsay, M. W. McCaffrey, and J. M. Tavare Rip11 is a Rab11- and AS160-RabGAP-binding protein required for insulin-stimulated glucose uptake in adipocytes J. Cell Sci., December 1, 2007; 120(23): 4197 - 4208. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. F. Kramer, E. B. Taylor, C. A. Witczak, N. Fujii, M. F. Hirshman, and L. J. Goodyear Calmodulin-Binding Domain of AS160 Regulates Contraction- but Not Insulin-Stimulated Glucose Uptake in Skeletal Muscle Diabetes, December 1, 2007; 56(12): 2854 - 2862. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. B. Arias and G. D. Cartee In vitro simulation of calorie restriction-induced decline in glucose and insulin leads to increased insulin-stimulated glucose transport in rat skeletal muscle Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1782 - E1788. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Saito, C. C. Jones, S. Huang, M. P. Czech, and P. F. Pilch The Interaction of Akt with APPL1 Is Required for Insulin-stimulated Glut4 Translocation J. Biol. Chem., November 2, 2007; 282(44): 32280 - 32287. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Falasca, W. E. Hughes, V. Dominguez, G. Sala, F. Fostira, M. Q. Fang, R. Cazzolli, P. R. Shepherd, D. E. James, and T. Maffucci The Role of Phosphoinositide 3-Kinase C2{alpha} in Insulin Signaling J. Biol. Chem., September 21, 2007; 282(38): 28226 - 28236. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Yoshizaki, T. Imamura, J. L. Babendure, J.-C. Lu, N. Sonoda, and J. M. Olefsky Myosin 5a Is an Insulin-Stimulated Akt2 (Protein Kinase B{beta}) Substrate Modulating GLUT4 Vesicle Translocation Mol. Cell. Biol., July 15, 2007; 27(14): 5172 - 5183. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. F. Howlett, K. Sakamoto, A. Garnham, D. Cameron-Smith, and M. Hargreaves Resistance Exercise and Insulin Regulate AS160 and Interaction With 14-3-3 in Human Skeletal Muscle Diabetes, June 1, 2007; 56(6): 1608 - 1614. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. B. Arias, J. Kim, K. Funai, and G. D. Cartee Prior exercise increases phosphorylation of Akt substrate of 160 kDa (AS160) in rat skeletal muscle Am J Physiol Endocrinol Metab, April 1, 2007; 292(4): E1191 - E1200. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Sriwijitkamol, D. K. Coletta, E. Wajcberg, G. B. Balbontin, S. M. Reyna, J. Barrientes, P. A. Eagan, C. P. Jenkinson, E. Cersosimo, R. A. DeFronzo, et al. Effect of Acute Exercise on AMPK Signaling in Skeletal Muscle of Subjects With Type 2 Diabetes: A Time-Course and Dose-Response Study Diabetes, March 1, 2007; 56(3): 836 - 848. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. T. Treebak, J. B. Birk, A. J. Rose, B. Kiens, E. A. Richter, and J. F. P. Wojtaszewski AS160 phosphorylation is associated with activation of {alpha}2beta2{gamma}1- but not {alpha}2beta2{gamma}3-AMPK trimeric complex in skeletal muscle during exercise in humans Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E715 - E722. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. S.L. Thong, P. J. Bilan, and A. Klip The Rab GTPase-Activating Protein AS160 Integrates Akt, Protein Kinase C, and AMP-Activated Protein Kinase Signals Regulating GLUT4 Traffic Diabetes, February 1, 2007; 56(2): 414 - 423. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Hamada, E. B. Arias, and G. D. Cartee Increased submaximal insulin-stimulated glucose uptake in mouse skeletal muscle after treadmill exercise J Appl Physiol, November 1, 2006; 101(5): 1368 - 1376. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. McCarthy, K. O. Spisak, J. T. Brozinick, and J. S. Elmendorf Loss of cortical actin filaments in insulin-resistant skeletal muscle cells impairs GLUT4 vesicle trafficking |